Spero Therapeutics Licenses Innovent's Antibody Therapy in Deal Worth Up to $1.1 Billion
Spero Therapeutics secured a licensing deal worth up to $1.1 billion with Innovent Biologics and raised $105 million through a financing agreement with Healthcare Royalty, leading to premarket share gains.
Topics: biotech financing licensing agreement